Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 496 shares of the company’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $119.09, for a total value of $59,068.64. Following the transaction, the chief financial officer now directly owns 74,314 shares of the company’s stock, valued at approximately $8,850,054.26. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.
Michael Burkes Brophy also recently made the following trade(s):
- On Monday, October 21st, Michael Burkes Brophy sold 608 shares of Natera stock. The stock was sold at an average price of $120.76, for a total value of $73,422.08.
- On Wednesday, July 31st, Michael Burkes Brophy sold 1,866 shares of Natera stock. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90.
- On Monday, July 29th, Michael Burkes Brophy sold 1,238 shares of Natera stock. The stock was sold at an average price of $102.77, for a total transaction of $127,229.26.
- On Thursday, July 25th, Michael Burkes Brophy sold 690 shares of Natera stock. The shares were sold at an average price of $105.29, for a total transaction of $72,650.10.
Natera Stock Performance
Shares of NASDAQ:NTRA traded down $1.30 during midday trading on Wednesday, hitting $118.65. The stock had a trading volume of 632,741 shares, compared to its average volume of 1,331,355. The company has a market capitalization of $14.57 billion, a PE ratio of -38.03 and a beta of 1.53. Natera, Inc. has a 1 year low of $36.90 and a 1 year high of $133.54. The stock has a 50 day moving average price of $123.43 and a two-hundred day moving average price of $111.03. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34.
Wall Street Analyst Weigh In
Several equities analysts have issued reports on the stock. TD Cowen upped their price objective on shares of Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group raised their price target on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research note on Tuesday, August 27th. Stephens reiterated an “overweight” rating and issued a $125.00 price objective on shares of Natera in a research note on Friday, August 9th. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research report on Thursday, October 17th. Finally, Morgan Stanley lifted their target price on shares of Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. One research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Natera currently has a consensus rating of “Moderate Buy” and a consensus price target of $124.44.
Read Our Latest Research Report on NTRA
Institutional Investors Weigh In On Natera
A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Vanguard Group Inc. increased its holdings in shares of Natera by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock valued at $1,010,152,000 after purchasing an additional 72,848 shares in the last quarter. Farallon Capital Management LLC grew its position in Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after buying an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Natera by 6.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after buying an additional 148,917 shares in the last quarter. Duquesne Family Office LLC lifted its position in shares of Natera by 2.4% during the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock valued at $213,860,000 after acquiring an additional 45,500 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in shares of Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after acquiring an additional 246,246 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.
Natera Company Profile
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Featured Stories
- Five stocks we like better than Natera
- Energy and Oil Stocks Explained
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Market Cap Calculator: How to Calculate Market Cap
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.